Transamerica Financial Advisors LLC Invests $2.50 Million in Alnylam Pharmaceuticals, Inc. $ALNY

Transamerica Financial Advisors LLC acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 8,288 shares of the biopharmaceutical company's stock, valued at approximately $2,495,000.

A number of other institutional investors also recently made changes to their positions in the business. Brighton Jones LLC bought a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth $243,000. Geneos Wealth Management Inc. raised its stake in shares of Alnylam Pharmaceuticals by 372.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company's stock valued at $60,000 after purchasing an additional 175 shares in the last quarter. Flow Traders U.S. LLC bought a new position in shares of Alnylam Pharmaceuticals during the second quarter worth about $241,000. Daiwa Securities Group Inc. lifted its position in shares of Alnylam Pharmaceuticals by 0.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company's stock worth $4,220,000 after buying an additional 35 shares during the last quarter. Finally, NewEdge Advisors LLC grew its position in shares of Alnylam Pharmaceuticals by 70,300.0% during the 2nd quarter. NewEdge Advisors LLC now owns 704 shares of the biopharmaceutical company's stock valued at $229,000 after buying an additional 703 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Down 0.4%

ALNY opened at $239.00 on Thursday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $197.81 and a 12 month high of $495.55. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99. The stock has a market cap of $31.98 billion, a P/E ratio of 44.42 and a beta of 0.30. The stock's 50 day moving average price is $264.27 and its 200 day moving average price is $294.77.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The company had revenue of $1.29 billion during the quarter, compared to analyst estimates of $1.32 billion. During the same quarter in the previous year, the firm posted ($0.51) EPS. The firm's quarterly revenue was up 66.9% on a year-over-year basis. As a group, research analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.59 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ALNY has been the topic of several research reports. Needham & Company LLC dropped their price objective on shares of Alnylam Pharmaceuticals from $510.00 to $357.00 and set a "buy" rating on the stock in a research note on Thursday, July 30th. Weiss Ratings upgraded Alnylam Pharmaceuticals from a "hold (c-)" rating to a "hold (c)" rating in a research report on Friday, July 31st. Oppenheimer lowered their price objective on Alnylam Pharmaceuticals from $500.00 to $350.00 and set an "outperform" rating for the company in a research note on Friday, July 31st. Wall Street Zen lowered Alnylam Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Sunday, August 2nd. Finally, Truist Financial cut their target price on Alnylam Pharmaceuticals from $410.00 to $315.00 and set a "buy" rating on the stock in a research note on Tuesday, August 4th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $386.14.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the firm's stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the transaction, the director owned 1,582 shares of the company's stock, valued at approximately $473,302.76. This trade represents a 70.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.86% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source